MoonLake Immunotherapeutics (MLTX) to Release Earnings on Monday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is expected to be releasing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect MoonLake Immunotherapeutics to post earnings of ($0.91) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.92). During the same quarter in the previous year, the business earned ($0.72) earnings per share. On average, analysts expect MoonLake Immunotherapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock traded up $0.84 during midday trading on Monday, reaching $17.57. The company had a trading volume of 101,705 shares, compared to its average volume of 1,723,363. The company has a market capitalization of $1.26 billion, a P/E ratio of -4.97 and a beta of 1.02. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The firm’s fifty day simple moving average is $17.55 and its 200-day simple moving average is $15.03. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27.

Wall Street Analyst Weigh In

MLTX has been the topic of a number of research reports. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their target price for the stock from $8.00 to $10.00 in a research note on Wednesday, January 14th. Oppenheimer raised their target price on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. HC Wainwright raised their target price on shares of MoonLake Immunotherapeutics from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wolfe Research raised shares of MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and raised their target price for the stock from $12.00 to $24.00 in a research note on Monday, March 23rd. Finally, Needham & Company LLC raised their target price on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Nine investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has an average rating of “Hold” and an average target price of $23.08.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il sold 3,750,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total transaction of $62,962,500.00. Following the sale, the director owned 1,039,238 shares of the company’s stock, valued at approximately $17,448,806.02. The trade was a 78.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07. Following the sale, the chief executive officer directly owned 2,976,766 shares in the company, valued at approximately $54,802,262.06. The trade was a 3.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,900,000 shares of company stock worth $65,714,663 over the last three months. Corporate insiders own 12.02% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

Institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at approximately $26,000. Bank of America Corp DE raised its position in shares of MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after buying an additional 3,166 shares during the period. Russell Investments Group Ltd. raised its position in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at approximately $47,000. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.